Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities
  • Price (EUR)261.60
  • Today's Change-6.30 / -2.35%
  • Shares traded0.00
  • 1 Year change-44.04%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Humana Inc. is a healthcare company. It operates through two segments: Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly through group Medicare accounts. It also includes its contract with the Centers for Medicare and Medicaid Services (CMS) to administer the Limited Income Newly Eligible Transition (LI-NET), a prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. It also includes products consisting of employer group commercial fully insured medical and specialty health insurance benefits. The CenterWell segment includes pharmacy solutions, primary care, and home solutions operations. It also includes its strategic partnerships with Welsh, Carson, Anderson & Stowe (WCAS) to develop and operate senior-focused, payor-agnostic, primary care centers, as well as a minority ownership interest in Gentiva Hospice operations.

  • Revenue in USD (TTM)115.01bn
  • Net income in USD1.36bn
  • Incorporated1964
  • Employees67.60k
  • Location
    Humana Inc500 W Main StLOUISVILLE 40202United StatesUSA
  • Phone+1 (502) 580-1000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.humana.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.